US Stock MarketDetailed Quotes
AVTE Aerovate
- 2.700
- +0.020+0.75%
Close Jan 6 16:00 ET
78.06MMarket Cap-0.90P/E (TTM)
2.710High2.678Low280.56KVolume2.680Open2.680Pre Close756.44KTurnover2.36%Turnover RatioLossP/E (Static)28.91MShares32.41552wk High0.97P/B32.10MFloat Cap1.25052wk Low--Dividend TTM11.89MShs Float32.415Historical High--Div YieldTTM1.21%Amplitude1.250Historical Low2.696Avg Price1Lot Size
Aerovate Stock Forum
Sign in to post a comment
$Aerovate (AVTE.US)$ thanks in 2,40 out 2,89
2
4
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Aerovate (AVTE.US)$ good volume kick in
$Aerovate (AVTE.US)$ seems not good to me
$Aerovate (AVTE.US)$ not moving yet
1
$Aerovate (AVTE.US)$ Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
$Aerovate (AVTE.US)$
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases
Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025
Approximately $300 million raised to date, including anticipated...
1
No comment yet
Heat List
US
Overall
Symbol
Price
% Chg
No Data
103892611 : yes
WeiTheSaint469 OP : thank God I got out lol